Browsing: “We are encouraged by the immunogenicity and safety profile of mRNA-1273 in children aged 6 to under 12 years and are pleased that the study met its primary immunogenicity endpoints
Moderna reported that its two-dose vaccine generated virus-neutralizing antibodies in children, and safety was comparable to what was previously seen in clinical trials of adolescents and adults.